Shares of Sun Pharmaceutical Ltd. fell nearly 2% on Monday after the company received eight observations from US Food and Drug Administration on Saturday.
On June 14, drug major Sun Pharma said the US health regulator has issued a Form 483 with eight observations after inspecting its Halol (Gujarat) manufacturing plant.
-
Indian Markets Turning Corner After Two Tough Years, Says Sandeep Tandon -
NDTV Profit Ignite 2026: Experts See Opportunity In Equities, Stay Bullish For Long-Term -
Buy Right, Sit Tight Does Not Work for Individual Stocks, Says Dinshaw Irani -
'Worst Is Behind': Quant MF Sees Market Bottom, Flags 'Extreme Euphoria' In Midcaps -
India's Mutual Fund Industry Could Become A $1 Trillion Opportunity, Say Fund Managers -
'Foreign Investors Are Baraatis': Raamdeo Agrawal's Take On LTCG Tax -
Stay Invested Through Market Cycles: Raamdeo Agrawal at NDTV Profit Ignite -
Ramesh Damani Remains Bullish On India For Next 20-30 Years, Sees Bargains Amid Market Weakness -
CAS Came After A Long Consultation Process: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFIT IGNITE -
Aim To Cut FPI Onboarding Time From Mth To Five Days: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFI
The US FDA conducted a good manufacturing practices inspection at the Halol facility from June 2-13, 2025, the Mumbai-based drug maker said in a regulatory filing.
At the conclusion of the inspection, the USFDA issued a Form-483 with 8 observations, it added.
As per the USFDA, Form 483 is issued to a firm's management at the conclusion of an inspection when the investigator has observed any conditions that may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.
Sun Pharma Share Price
Shares of Sun Pharma fell as much as 1.90% to Rs 1,655.70 apiece. They pared losses to trade 0.11% lower at Rs 1,685.90 apiece, as of 9:25 a.m. This compares to a 0.36% advance in the NSE Nifty 50.
The stock has risen 11.36% in the last 12 months and fallen 10.56% year-to-date. Total traded volume so far in the day stood at 2.90 times its 30-day average. The relative strength index was at 61.16.
Out of 43 analysts tracking the company, 35 maintain a 'buy' rating, five recommend a 'hold' and three suggest 'sell', according to Bloomberg data. The average 12-month consensus price target implies an upside of 18.6%.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.